Nuvation Bio (NUVB) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US67080N1019
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative therapeutic candidates for oncology treatment.
The company's flagship product, NUV-868, is a cutting-edge oral small molecule BET inhibitor that plays a crucial role in epigenetically regulating proteins responsible for managing tumor growth and differentiation, including prominent oncogenes like c-myc.
Additionally, Nuvation Bio Inc. offers NUV-1156, an AR binder Xtandi tailored to combat advanced-stage prostate cancers, with the potential to transition into earlier treatment lines that are typically addressed through surgical prostatectomy.
Moreover, the company boasts a drug-drug conjugate (DDC) platform that zeroes in on targeting an inhibitor of poly ADP ribose polymerase (PARP) to the anti-cancer warheads of existing drugs, alongside NUV-1176, a PARP inhibitor specifically designed to tackle ER+ breast and ovarian cancer.
Established in 2018, Nuvation Bio Inc. is headquartered in New York, New York, and continues to be a trailblazer in the field of biopharmaceutical innovation. To learn more about the company, visit their website at https://www.nuvationbio.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
NUVB Stock Overview
| Market Cap in USD | 646m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2020-08-24 |
NUVB Stock Ratings
| Growth 5y | -4.22 |
| Fundamental | -74.8 |
| Dividend | - |
| Rel. Performance vs Sector | 6.32 |
| Analysts | 4.67/5 |
| Fair Price Momentum | 3.48 USD |
| Fair Price DCF | - |
NUVB Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
NUVB Growth Ratios
| Growth 12m | 100.00% |
| Growth Correlation 12m | 23% |
| Growth Correlation 3m | 58% |
| CAGR 5y | -26.33% |
| Sharpe Ratio 12m | 1.16 |
| Alpha vs SP500 12m | 69.17 |
| Beta vs SP500 5y weekly | 1.17 |
| ValueRay RSI | 85.18 |
| Volatility GJR Garch 1y | 82.03% |
| Price / SMA 50 | 16.67% |
| Price / SMA 200 | 77.9% |
| Current Volume | 710.1k |
| Average Volume 20d | 1160.6k |
External Links for NUVB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 09, 2024, the stock is trading at USD 3.22 with a total of 710,144 shares traded.
Over the past week, the price has changed by +0.63%, over one month by -0.31%, over three months by +89.41% and over the past year by +98.77%.
According to ValueRays Forecast Model, NUVB Nuvation Bio will be worth about 3.9 in May 2025. The stock is currently trading at 3.22. This means that the stock has a potential upside of +21.12%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 5.9 | 83.2 |
| Analysts Target Price | 4.1 | 26.7 |
| ValueRay Target Price | 3.9 | 21.1 |